FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1972-1977 November 4, 2004 Number 19 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Feany, M. B. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease.

Methods A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews.

Results Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [±SD] age at onset, 60.0±14.2 years vs. 64.2±11.7 years; P=0.04).

Conclusions Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.

Source Information

From the Department of Neurology and the Cognitive Neurology Unit (J.A.-P.) and the Departments of Hematology and Bone Marrow Transplantation (H.R.) and Human Genetics (R.G.-B.), Rambam Medical Center; and the Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology (J.A.-P., H.R., R.G.-B.) — both in Haifa, Israel.

Address reprint requests to Dr. Gershoni-Baruch at the Department of Medical Genetics, Rambam Medical Center, Haifa 31096, Israel, or at rgershoni{at}rambam.health.gov.il.

Full Text of this Article

Related Letters:

The Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Eblan M. J., Walker J. M., Sidransky E., Zimran A., Neudorfer O., Elstein D., Schlossmacher M. G., Cullen V., Müthing J., Gershoni-Baruch R., Aharon-Peretz J., Rosenbaum H.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:728-731, Feb 17, 2005. Correspondence

This article has been cited by other articles:

• Caldwell, G. A., Caldwell, K. A. (2008). Traversing a wormhole to combat Parkinson's disease. DMM 1: 32-36 [Abstract] [Full Text]  
• Rogaeva, E., Hardy, J. (2008). Gaucher and Parkinson diseases: Unexpectedly related. Neurology 70: 2272-2273 [Full Text]  
• Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., Bar-Shira, A., Orr-Urtreger, A. (2008). Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70: 2277-2283 [Abstract] [Full Text]  
• Mata, I. F., Samii, A., Schneer, S. H., Roberts, J. W., Griffith, A., Leis, B. C., Schellenberg, G. D., Sidransky, E., Bird, T. D., Leverenz, J. B., Tsuang, D., Zabetian, C. P. (2008). Glucocerebrosidase Gene Mutations: A Risk Factor for Lewy Body Disorders. Arch Neurol 65: 379-382 [Abstract] [Full Text]  
• Capablo, J L, Saenz de Cabezon, A, Fraile, J, Alfonso, P, Pocovi, M, Giraldo, P, on behalf of the Spanish Group on Gaucher Disease, (2008). Neurological evaluation of patients with Gaucher disease diagnosed as type 1. J. Neurol. Neurosurg. Psychiatry 79: 219-222 [Abstract] [Full Text]  
• Clark, L. N., Ross, B. M., Wang, Y., Mejia-Santana, H., Harris, J., Louis, E. D., Cote, L. J., Andrews, H., Fahn, S., Waters, C., Ford, B., Frucht, S., Ottman, R., Marder, K. (2007). Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69: 1270-1277 [Abstract] [Full Text]  
• Wu, Y.-R., Chen, C.-M., Chao, C.-Y., Ro, L.-S., Lyu, R.-K., Chang, K.-H., Lee-Chen, G.-J. (2007). Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J. Neurol. Neurosurg. Psychiatry 78: 977-979 [Abstract] [Full Text]  
• Tan, E.-K., Tong, J., Fook-Chong, S., Yih, Y., Wong, M.-C., Pavanni, R., Zhao, Y. (2007). Glucocerebrosidase Mutations and Risk of Parkinson Disease in Chinese Patients. Arch Neurol 64: 1056-1058 [Full Text]  
• Lees, A. J., Singleton, A. B. (2007). Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology 68: 1553-1554 [Full Text]  
• Di Fonzo, A., Chien, H. F., Socal, M., Giraudo, S., Tassorelli, C., Iliceto, G., Fabbrini, G., Marconi, R., Fincati, E., Abbruzzese, G., Marini, P., Squitieri, F., Horstink, M. W., Montagna, P., Libera, A. D., Stocchi, F., Goldwurm, S., Ferreira, J. J., Meco, G., Martignoni, E., Lopiano, L., Jardim, L. B., Oostra, B. A., Barbosa, E. R., The Italian Parkinson Genetics Network, , Bonifati, V. (2007). ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68: 1557-1562 [Abstract] [Full Text]  
• Goker-Alpan, O., Giasson, B. I., Eblan, M. J., Nguyen, J., Hurtig, H. I., Lee, V. M.-Y., Trojanowski, J. Q., Sidransky, E. (2006). Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 67: 908-910 [Abstract] [Full Text]  
• Spitz, M, Rozenberg, R, Silveira, P A A, Barbosa, E R (2006). Parkinsonism in type 1 Gaucher's disease. J. Neurol. Neurosurg. Psychiatry 77: 709-710 [Full Text]  
• Toft, M., Pielsticker, L., Ross, O. A., Aasly, J. O., Farrer, M. J. (2006). Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 66: 415-417 [Abstract] [Full Text]  
• Aharon-Peretz, J., Badarny, S., Rosenbaum, H., Gershoni-Baruch, R. (2005). Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype-genotype correlation. Neurology 65: 1460-1461 [Abstract] [Full Text]  
• Halliday, G. M., Ophof, A., Broe, M., Jensen, P. H., Kettle, E., Fedorow, H., Cartwright, M. I., Griffiths, F. M., Shepherd, C. E., Double, K. L. (2005). {alpha}-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128: 2654-2664 [Abstract] [Full Text]  
• Paisan-Ruiz, C., Lang, A. E., Kawarai, T., Sato, C., Salehi-Rad, S., Fisman, G. K., Al-Khairallah, T., St George-Hyslop, P., Singleton, A., Rogaeva, E. (2005). LRRK2 gene in Parkinson disease: Mutation analysis and case control association study. Neurology 65: 696-700 [Abstract] [Full Text]  
• Eblan, M. J., Walker, J. M., Sidransky, E., Zimran, A., Neudorfer, O., Elstein, D., Schlossmacher, M. G., Cullen, V., Muthing, J., Gershoni-Baruch, R., Aharon-Peretz, J., Rosenbaum, H. (2005). The Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews. NEJM 352: 728-731 [Full Text]